Key Updates in the Treatment of HER2-Positive Breast Cancer

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

More than half of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop brain metastases. Several newly approved HER2-targeted drugs with different mechanisms of action are showing promise in this setting, one of which is able to cross the blood-brain barrier. In this activity, a breast cancer specialist looks at current and emerging HER2-targeted therapies, their mechanisms of action, the clinical trials supporting their benefits in patients with metastatic disease, and best practices for managing treatment-related adverse events.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Apply current evidence and guideline recommendations to identify the appropriate use of and optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer
Implement best practices for the management of HER2-positive breast cancer brain metastases
Develop strategies to effectively manage adverse events associated with treatments for HER2-positive breast cancer